New drug could extend lives of people with deadly bone cancer

Mice treated with the med lived 50% longer.

One in three people with primary bone cancer will die within five years of diagnosis — but a new drug has the potential to help patients live longer without subjecting them to painful or unpleasant treatments.

The challenge: Cancer that starts in the bones is rare, with fewer than 4,000 new diagnoses every year in the US. However, 25% of those cases are people under the age of 20, and because bone cancer spreads rapidly, treatments are often drastic.

“Currently children have to undergo very toxic treatment, which has very unpleasant and sometimes life-long side effects, and sometimes life-changing amputation,” said co-author Alison Gartland from the University of Sheffield.

“It would be a much kinder treatment for children with bone cancer.”

Darrell Green

What’s new? Now, Garland and colleagues from the University of East Anglia (UEA) are developing a new bone cancer treatment that they hope will not only be more effective, but also more tolerable for patients.

For their latest study, the team used sequencing technology to analyze bone and tumor samples donated by 19 patients. This led to the discovery that a gene called RUNX2 is activated in bone cancer.

According to the researchers, the protein this gene expresses is not usually required by normal cells, but it does help bone cancer spread, so they developed a drug, called “CADD522,” that blocks its effect.

“We want to save lives and reduce the amount of disability caused by surgery.”

Darrell Green

In preclinical trials of mice implanted with human bone cancer, CADD522 increased metastasis-free survival rates by 50%. That means treated animals lived 50% longer than untreated animals before they had to be put down due to effects of their cancer spreading.

“The new drug that we have developed is effective in all of the main bone cancer subtypes and, so far, our experiments show that it is not toxic to the rest of the body,” lead researcher Darrell Green from the UEA told BBC News.

“This means that it would be a much kinder treatment for children with bone cancer, compared to the grueling chemotherapy and life-changing limb amputation that patients receive today,” he continued.

Looking ahead: The drug is now undergoing more testing so that the researchers will have the data needed to seek approval for a clinical trial. 

Many treatments that work in mice don’t translate to people, but Green — who lost a childhood friend to bone cancer — is optimistic about this one.

“Ultimately, we want to save lives and reduce the amount of disability caused by surgery,” he said, “and now we have developed a new drug that potentially promises to do just that.”

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Related
Is iron the Achilles’ heel for cancer?
Some cancer cells store high quantities of iron. Iron-activated cancer drugs selectively disrupt cancer cells, without harming healthy cells.
Octopus tentacle-like patch delivers drugs through your cheek
A needle-free drug delivery system inspired by octopus tentacles could one day replace injections for administering biopharmaceuticals.
New “multipronged” gene therapy reverses paralysis in mice
A new gene therapy that guides nerve regeneration across complete spinal cord injuries restored the ability to walk in paralyzed mice.
An implantable device could enable injection-free control of diabetes
MIT engineers designed an implantable device that carries islet cells along with its own on-board oxygen factory to keep the cells healthy.
New “inverse vaccines” could be key to curing autoimmune disorders
“Inverse vaccines” that teach the immune system to tolerate triggering molecules could be the key to curing autoimmune disorders.
Up Next
doctors in lab coats performing a procedure on a patient
Subscribe to Freethink for more great stories